
CLINICAL INTERESTS:
Cardio-Oncology, Cardio-Immunology
RESEARCH INTERESTS:
I am a cardiologist and myocyte biologist. My clinical focus is cardio-oncology and cardio-immunology. My clinical interests overlap with my laboratory focus, where we are investigating the mechanistic underpinnings of cardiovascular sequelae of novel targeted and immune-based cancer therapies.
Since 2016, a major focus of my clinical and research program has been the interaction between the cardiovascular and immune systems. Our group initially described a novel clinical syndrome of fulminant myocarditis that arises from (ICI) immune checkpoint inhibitors (Johnson et al, NEJM, 2016). We further defined the clinical characteristics of ICI-associated myocarditis (Moslehi et al, Lancet, 2018) and showed that cardiovascular sequelae of ICI include pericarditis, vasculitis and arrhythmias (Salem et al, Lancet Oncology, 2018). My laboratory has generated mouse models that recapitulate these novel immune-based clinical syndromes which have provided insights into new diagnostic and treatment strategies for these complications (Bonaca et al, Circulation, 2019; Salem et al, NEJM, 2019; Wei et al, Cancer Discovery, 2021). My interest in this space has recently expanded to other inflammatory cardiomyopathies, including giant cell myocarditis, acute cellular rejection (ACR) following cardiac transplantation, and other forms of myocarditis. Our group is further investigating the how the immune system can be harnessed to treat heart disease.
Publications
Cardiovascular safety outcomes of chronic lymphocytic leukemia treatments: A systematic and targeted literature review.
Immune checkpoint inhibitor-associated myocarditis: a novel risk score.
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.
Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report.
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
A PHASE 1 FIRST-IN-HUMAN STUDY OF THE MCL-1 INHIBITOR AZD5991 IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES.
Cardio-Oncology: A New Clinical Frontier and Novel Platform for Cardiovascular Investigation.
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology.
Unveiling Cellular Identities and Gene Expression Pathways in Overlapping Myocarditis and Myositis.
Clonal Hematopoiesis and Inflammation in the VasculaturE (CHIVE): a prospective, longitudinal cohort and biorepository.
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart.
Autoimmune Myocarditis, Old Dogs and New Tricks.
Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity.
Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
PD-1-PD-L1 immunomodulatory pathway regulates cardiac regeneration.
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective.
Publisher Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
B-Cell Immune Checkpoints Come of Age in Cardio-oncology.
Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response.
Genetic Interleukin-6 Receptor Variant Is Not Associated With Rejection and Mortality After Heart Transplantation.
Author Correction: Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
CTLA-4 Pathway Is Instrumental in Giant Cell Arteritis.
Immune Checkpoint Inhibitors' Effects on Calcified Aortic Plaques in Melanoma Survivors: A Retrospective Cohort Study.
Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis.
Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multicenter study.
Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis.
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma.
Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Circulating immune checkpoints predict heart failure outcomes.
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Addressing cardiovascular complications of BTK inhibitors.
Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review.
Immune Checkpoint Inhibitor Myocarditis Treatment Strategies and Future Directions.
Single-Nuclear RNA Sequencing of Endomyocardial Biopsies Identifies Persistence of Donor-Recipient Chimerism With Distinct Signatures in Severe Cardiac Allograft Vasculopathy.
Heightened apoptotic priming of vascular cells across tissues and life span predisposes them to cancer therapy-induced toxicities.
Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis.
Reply to S. Rossi et al and P. Palassin et al.
A Pilot Study of Associations Between the Occurrence of Palpitations and Cytokine Gene Variations in Women Prior to Breast Cancer Surgery.
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Immune-Checkpoint Inhibitor (ICI) resumption after severe graft injury in a heart transplant recipient with nivolumab-sensitive metastatic melanoma and renal cell carcinoma.
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry.
Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism.
Reply to S. Tan et al.
AGS and NIA bench-to bedside conference summary: Cancer and cardiovascular disease.
Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program.
Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis.
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer.
Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.
Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis.
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.
18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis.
Immune-checkpoint inhibitors: long-term implications of toxicity.
Harnessing big data to characterize immune-related adverse events.
Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database.
Editorial: Recent Advances in Cardiotoxicity Testing.
Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis: A Narrative Review.
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study.
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation.
High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
Survivorship, Version 1.2021.
Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
RNA-Sequencing Reveals a Distinct Transcriptomic Signature for Giant Cell Myocarditis and Identifies Novel Druggable Targets.
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors.
Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association.
High-grade heart block associated with ibrutinib therapy.
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
Standing at the Crossroads.
Global Longitudinal Strain in Cardio-Oncology.
Implementation of Cardio-Oncology Training for Cardiology Fellows.
Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors.
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document.
Age-Related Considerations in Cardio-Oncology.
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study.
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
The cancer patient and cardiology.
Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer.
Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity.
Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.
Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research.
NCCN Guidelines Insights: Survivorship, Version 2.2020.
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy.
Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.
Tissue Is the Issue, Even During a Pandemic.
Inflammation begets inflammation: cancer and acute MI.
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis.
Vascular medicine and cardio-oncology - A new, evolving clinical frontier.
Cardiac Events Associated With Chimeric Antigen Receptor T-Cells (CAR-T): A VigiBase Perspective.
Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis.
COVID-19 and immune checkpoint inhibitors: initial considerations.
Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes.
Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.
Solid organ transplant rejection associated with immune-checkpoint inhibitors.
Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses.
Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.
Cardio-Immuno-Oncology.
The 2019 Nobel Prize honors fundamental discoveries in hypoxia response.
Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events: From Mechanism to Patient Care.
Corrigendum to "Assessing cardiac safety in oncology drug development" [Am Heart J 214 (2019) 125-133].
Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.
Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group.
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology.
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study.
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors.
Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.
Cancer cachexia: getting to the heart of the matter.
Cardiovascular Toxicities Associated With Ibrutinib.
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.
Comparative Transcriptomics of Ex Vivo, Patient-Derived Endothelial Cells Reveals Novel Pathways Associated With Type 2 Diabetes Mellitus.
Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.
Fulminant Myocarditis: Evolving Diagnosis, Evolving Biology, Evolving Prognosis.
A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis.
NCCN Guidelines Insights: Survivorship, Version 2.2019.
Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis.
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.
Assessing cardiac safety in oncology drug development.
Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need.
Cardiovascular toxicities associated with immune checkpoint inhibitors.
Immune checkpoint inhibitor-associated hypophysitis-World Health Organisation VigiBase report analysis.
Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer: A Review.
Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week.
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.
Hematologic Complications of Immune Checkpoint Inhibitors.
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy.
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
The forgotten right ventricle in cardio-oncology.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.
Immune checkpoint inhibitors and cardiovascular toxicity.
Hidden Figures: Occult Intra-Cardiac Metastases in Asymptomatic Neuroendocrine Tumor Patients.
Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.
Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention.
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.
Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers.
In Silico Pharmacoepidemiologic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers.
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms.
Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase.
Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic.
Radiation-Induced Cardiovascular Toxicity: Mechanisms, Prevention, and Treatment.
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Comorbidities: Cardiovascular disease and breast cancer.
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.
Smoldering myocarditis following immune checkpoint blockade.
Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.
Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.
Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Cardio-Oncology: Vascular Endothelial Growth Factor Inhibitors, Salt, and Macrophages: A Complicated Interaction.
Cardiovascular Toxicities Associated with Cancer Immunotherapies.
Cardio-Oncology: Time to Get More Mechanistic.
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
Myocarditis with Immune Checkpoint Blockade.
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.
NCCN Guidelines Insights: Survivorship, Version 1.2016.
Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty.
Cardiovascular disease following hematopoietic stem cell transplantation: Pathogenesis, detection, and the cardioprotective role of aerobic training.
Cardiology Patient Page. ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis.
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
QT Prolongation and Oncology Drug Development.
Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes.
Survivorship: screening for cancer and treatment effects, version 2.2014.
Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology.
Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary.
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
Survivorship: healthy lifestyles, version 2.2014.
Survivorship: immunizations and prevention of infections, version 2.2014.
Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase.
Survivorship: cognitive function, version 1.2014.
Survivorship: fatigue, version 1.2014.
Survivorship: sleep disorders, version 1.2014.
Survivorship: pain version 1.2014.
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Heart failure and breast cancer therapies: moving towards personalized risk assessment.
Real-time three-dimensional transoesophageal echocardiography enables preoperative pulmonary valvulopathy assessment.
Cancer-drug discovery and cardiovascular surveillance.
A Pkd1-Fbn1 genetic interaction implicates TGF-β signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease.
MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling.
Emerging paradigms in cardiomyopathies associated with cancer therapies.
Cardio-oncology: it takes two to translate.
Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease.
The cardiovascular perils of cancer survivorship.
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy.
Breast cancer therapies and cardiomyopathy.
Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.
Management of antiangiogenic therapy-induced hypertension.
Telomeres and mitochondria in the aging heart.
You can't run from inflammation: lower extremity ischemia, hypoxia signaling, and macrophage subtypes.
Reversible cardiomyopathy associated with sunitinib and sorafenib.
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo.
Paragangliomas: etiology, presentation, and management.
Hepatocellular carcinoma with intracavitary cardiac involvement: a case report and review of the literature.
cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells.
Nucleated conformational conversion and the replication of conformational information by a prion determinant.
Yeast prion [psi +] and its determinant, Sup35p.
Influence of antigen organization on the development of lupus autoantibodies.
Perforin protects against autoimmunity in lupus-prone mice.
Roles of interferon-gamma and interleukin-4 in murine lupus.
555 Mission Bay Blvd South, Rm 001
UCSF Box 3120
San Francisco, CA 94158
United States